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Summary
 
CD22 is a B cell–specific transmembrane glycoprotein that acts to dampen signals generated
through the B cell antigen receptor (BCR): B cells from CD22-deficient mice give increased
 
Ca
 
2
 
1
 
 fluxes on BCR ligation. Here we show that this B cell hyperresponsiveness correlates
with the development of autoantibodies. After the age of eight months, CD22-deficient mice
developed high titers of serum IgG directed against double-stranded DNA; these antibodies
were of multiclonal origin, somatically mutated, and high affinity. Increased titers of antibodies
to cardiolipin and myeloperoxidase were also noted. The results demonstrate that a single gene
defect exclusive to B lymphocytes is, without additional contrivance, sufficient to trigger auto-
antibody development in a large proportion of aging animals. Thus, CD22 might have evolved
specifically to regulate B cell triggering thresholds for the avoidance of autoimmunity.
Key words: B lymphocyte • autoimmunity • threshold • CD22 • inhibitory receptor
 
S
 
everal autoimmune diseases are characterized by the pres-
ence in serum of high affinity antibodies to self antigens,
with the B cells producing them having undergone heavy
chain class switching and somatic hypermutation. This sug-
gests that T cell help has been available, at least under these
pathological conditions, to facilitate maturation of an anti-
self response. The defect is, however, unlikely to lie simply
in the inappropriate provision of T cell help: several models
reveal that multiple loci can contribute to predisposition to
autoimmune disease (1–4), with intrinsic defects in the B
cell lineage able to play an important role (5, 6).
 
Although defects in B cell apoptosis can certainly acceler-
ate autoimmune disease (7), several lines of evidence suggest
that an intrinsic hyperresponsiveness of B cells to antigen
encounter could also be a contributory cause of autoimmu-
nity. Thus, genetic dissection of the contributing loci in a
mouse model of systemic lupus erythematosus reveals that
 
one of the loci (
 
Sle2
 
) leads to B cell hyperactivity (8). Fur-
thermore, the response to self antigen by B cells that express
an autoreactive immunoglobulin transgene can be signifi-
cantly affected by mutations that affect B cell antigen recep-
 
tor
 
 
 
(BCR)
 
1
 
 signaling (9, 10).
We were interested in determining whether mutations
affecting B cell signaling would be sufficient to predispose
autoantibody development in an otherwise normal mouse.
Is a hyperresponsiveness that is restricted to the B cell com-
partment nevertheless sufficient to so perturb the immune
system that the necessary help is recruited to allow devel-
opment of high affinity antiself antibodies?
To this end, we made use of CD22-deficient mice, which
exhibit a relatively mild B cell hyperresponsiveness (11–14).
CD22 is a B cell–specific transmembrane glycoprotein that
associates with BCR and possesses an extracellular domain
 
that binds 
 
a
 
-2,6-sialylated glycoconjugates (15–18). It acts
as a negative regulator of antigen receptor signaling, with
levels of BCR cross-linking that are too low to generate a
detectable signal in B cells from control mice, nevertheless
giving rise to a calcium flux with CD22-deficient B cells
(11–14). Indeed, even halving the abundance of CD22 on
the cell surface leads to enhanced BCR signaling (19). In
 
our initial characterization of CD22-deficient mice, we
 
noted a small (approximately
 
 
 
twofold) increase in total se-
rum IgM (but not IgG) together with a corresponding in-
crease in total Ig anti-DNA titers in 5-mo-old animals that
might be ascribable to an expanded B1 cell population (11).
However, here we show that as the CD22-deficient mice
age, they have a dramatically increased likelihood of pro-
ducing somatically mutated, high affinity autoreactive IgG.
Thus, it appears that there is tight regulation of BCR sig-
naling and that the perturbations caused by CD22 defi-
ciency can trigger the development of autoimmunity.
 
1
 
Abbreviations used in this paper: 
 
BCR, B cell antigen receptor; ds, double-
stranded; ES, embryonic stem cell.  
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Materials and Methods
 
Mice.
 
Mice were generated from chimeras established using a
previously described embryonic stem cell (ES) clone (11) contain-
ing a targeted integration of a 
 
tk-neo
 
 cassette into 
 
Cd22
 
. The chi-
meras (created using C57BL/6 blastocysts) were bred against both
C57BL/6 and BALB/c mice, and mice from the F2 generation
were maintained for up to 20 mo with tail bleeds taken every 4–6
wk. A cohort of control (129 
 
3
 
 C57BL/6)F2 mice (that do not
carry any targeted gene alteration) was established analogously. An-
imals were either bred in our own conventional facility or in a spe-
cific pathogen-free (barrier) unit following delivery by Caesarian
section and fostering onto C57BL/6 
 
3
 
 CBA females in isolators.
 
Analysis of Autoantibodies.
 
Serum titers of IgG anti–double-
stranded (ds) DNA were measured as described elsewhere (20)
using alkaline phosphatase–conjugated goat anti–mouse IgG
(Sigma Chemical Co., Ltd.). Sera from four MRL/lpr
 
 
 
mice were
always titered in parallel, with one of these sera assigned a titer
of 5 U/ml. The assay was calibrated using a high affinity IgG2a
monoclonal anti-dsDNA antibody (S22) from mouse 9612 (see
below); 1 U/ml in the ELISA was given by 24 
 
m
 
g/ml of S22. Ti-
ters of other IgG autoantibodies were similarly determined using
plates that had been coated with either cardiolipin (Sigma Chem-
ical Co.; 100 
 
m
 
g/ml in ethanol) or myeloperoxidase (Calbiochem
Corp.; 250 ng/ml in sodium bicarbonate, pH 9.2). Antibody iso-
types were determined using reagents from PharMingen.
Hybridomas were established from unimmunized mice by fu-
sion with NS0 cells and autoantibodies in the supernatants moni-
tored by ELISA developing with biotinylated goat anti–mouse 
 
k
 
(Southern Biotech) and alkaline phosphatase–conjugated strepta-
vidin (Dako). The binding of monoclonal anti-DNA antibodies
at 20
 
8
 
C to a 5
 
9
 
-biotinylated ds 48mer oligonucleotide that had
been immobilized on a streptavidin-coated chip (SA-Biacore
chip; Pharmacia) was monitored by surface plasmon resonance as
previously described (21).
 
Sequencing of Expressed V
 
H
 
 Segments.
 
Oligo-dT–primed cDNA
prepared from RNA extracted from the hybridomas was PCR
amplified using a consensus V
 
H
 
 oligonucleotide for forward prim-
ing (5
 
9
 
-CGGGATCCTGAGGTGCAGCTGGAGGAGTC [22])
 
in conjunction with either 5
 
9
 
-CGGAATTCGGGGCCAGTGG-
ATAGAC or 5
 
9
 
-CGGAATTCGGGACCAAGGGATAGAC for
priming back from the C
 
H
 
1 domain of C
 
g
 
1, 
 
g
 
2a, and 
 
g
 
b or of
C
 
g
 
3, respectively. PCR products were sequenced directly as well
as ligated into pUC18 with multiple DNA clones sequenced
from each hybridoma.
 
Results
 
We have previously described (11) an ES line (derived
from 129 mice) that carries a targeted integration of a neo-
mycin resistance gene into the CD22 gene; this cell line was
used to establish chimeric mice by injection into C57BL/6
blastocysts and germline transmission of the targeted allele
(yielding CD22
 
1
 
/
 
2
 
 heterozygotes) obtained following breed-
ing with both C57BL/6 and BALB/c females. Cohorts of
animals from the F2 generations of both sets of breedings
were followed with time for the development of IgG anti-
dsDNA antibody. On both backgrounds, high titers of
anti-DNA antibodies developed with age (particularly after
8 mo) in many of the CD22
 
2
 
/
 
2
 
 animals but not in the
CD22
 
1
 
/
 
1
 
 litter-matched controls. That the development
of these autoantibodies was due to the targeted integration
into the CD22 gene is confirmed by the fact that IgG anti-
dsDNA was not detected in the sera of control (129 
 
3
 
C57BL/6)F2 mice (Fig. 1).
The titer of anti-DNA antibody in the CD22-deficient
mice is, in many cases, of a comparable order to that found
in 12-mo-old MRL/lpr mice. By 18 mo of age, over 70%
of the CD22-deficient mice have at some time shown evi-
dence of IgG anti-dsDNA antibody in their sera at concen-
trations 
 
.
 
1.5 U/ml; none of the 42 control mice revealed
titers of this magnitude (Fig. 2). We have also followed a
limited number of CD22
 
1
 
/
 
2
 
 heterozygotes and found that
Figure 1. IgG anti-dsDNA
antibodies in the sera of CD22-
deficient and control mice. Se-
rum IgG anti-dsDNA was mea-
sured by ELISA and compared in
CD222/2 (center panels; j) and
CD221/1 littermates (left pan-
els;  e). These mice derive from
the F2 generation of conven-
tionally housed, CD22-targeted
ES chimeric mice bred against
BALB/c (top panels) or C57BL/6
(bottom panels). These cohorts
initially comprised 16 CD22-defi-
cient and 17 CD221/1 mice
from the BALB/c breedings and
21 CD22-deficient animals (25
CD221/1) from the C57BL/6
breedings. Elevated titers of IgG
anti-dsDNA were not detected
in sera of aged C57BL/6 or 129
control mice. In addition, the ti-
ters of IgG anti-dsDNA were monitored in the sera of 18 control (129 3 C57BL/6)F2 mice that did not carry a targeted gene modification (bottom right
panel) to exclude the possibility that a Cd22-linked polymorphism might result in autoantibody development in the context of a (129 3 C57BL/6)F2
background. The titers of IgG anti-DNA in sera of four MRL/lpr mice are indicated (s). Definition of units and calibration of the assay is described in
Materials and Methods. Autoantibody titers did not differ significantly between males and females. 
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3/11 had developed IgG anti-dsDNA by 12 mo of age (not
shown).
Life expectancy among CD22-deficient mice was de-
creased (10/43 weaned CD22-deficient mice having died
by 15 mo of age compared with 1/43 CD22
 
1
 
/
 
1
 
 controls),
with at least 4 of the deaths due to infection. However, all
but one of these deaths occurred after 7 mo of age. Fur-
thermore, we did not detect proteinuria or antibody depo-
sition in glomeruli in the mice harboring autoantibodies.
This lack of pathology may well correlate with the fact that
anti-DNA titers do not simply rise with age but, in individ-
ual animals, often rise, regress, and rise again.
dsDNA is not the sole target of autoantibody develop-
ment. Mice were also monitored for the development of
antibodies to cardiolipin and myeloperoxidase; a clear dis-
tinction between the CD22-deficient and control siblings
was found here as well (Table I and Fig. 3 A). The largest
cohort of animals was followed under conditions of con-
ventional housing, but we also compared autoantibody de-
 
velopment in CD22-deficient and control mice housed in a
barrier unit. The results (Table I) reveal that autoantibodies
also develop under these cleaner conditions.
Subclass typing of serum autoantibodies revealed that, in
both the C57BL/6 and BALB/c breedings, IgG2a anti-
DNA was found in 
 
z
 
80% of the autoimmune animals.
However, 
 
.
 
50% of the autoimmune mice contained anti-
DNA antibodies of multiple IgG subclasses. To obtain more
detail about the nature of these antibodies, hybridomas were
established from two unimmunized, 18-mo-old, CD22-defi-
cient females (mouse 9612 from the BALB/c breedings and
Figure 2. The percentage of CD22-deficient mice that have exhibited
serum IgG anti-DNA titers .1.5 U/ml at some stage during their lives,
plotted as a function of age. None of the control mice exhibited titers of
this magnitude.
Figure 3. ELISA titration of autoantibodies in CD22-deficient mice.
(A) Titers of serum IgG antibodies to cardiolipin (Card) and myeloperox-
idase (MPO) in the sera of 18-mo-old mice. Filled symbols, CD22-defi-
cient mice from the C57BL/6 breedings; mouse 9449 (j) and 9714 (r)
were conventionally housed, whereas 748 (m) was from the SPF facility.
Open symbols, litter-matched CD221/1 controls. (B) Titers of autoanti-
body in supernatants of hybridomas obtained from fusions performed on
CD22-deficient mice. Anti-DNA ELISA: S20 (j), S35 (r), and S48 (m)
with the cardiolipin-specific hybrid S19 (h) providing a negative control.
Anticardiolipin ELISA: S14 (m), S19 (j), S28 (.), and S72 (r) with hy-
brid S8 (e) providing a negative control. These hybrids all expressed IgG
antibodies (subclass and VH sequences are given in Fig. 5), but S14 and
S28 were Card-specific IgMs with unassigned VHs.
 
Table I.
 
Autoantibodies in the Sera of CD22-deficient and Control Mice
 
Antigen
Conventionally housed Barrier housed
12-mo-old 18-mo-old 14-mo-old
CD22
 
1
 
/
 
1
 
CD22
 
2
 
/
 
2
 
CD22
 
1
 
/
 
1
 
CD22
 
2
 
/
 
2
 
CD22
 
1
 
/
 
1
 
CD22
 
2
 
/
 
2
 
Cardiolipin 0/19
 
*
 
1/16 0/17 3/14 0/5 2/7
Myeloperoxidase 0/19 3/16 0/17 3/14 0/5 6/7
dsDNA 0/25 10/19 0/25 10/15 0/5 4/7
Serum IgG autoantibodies were monitored at the ages indicated. All mice are from the C57BL/6 breedings. Two of the conventionally housed
18-mo-old as well as two of the barrier-housed 14-mo-old CD22-deficient mice simultaneously harbored antibodies against cardiolipin, myeloper-
oxidase, and DNA.
 
*
 
Mice harboring autoantibodies/total mice. 
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9449 from the C57BL/6 breedings), as well as two CD22
 
1
 
/
 
1
 
litter-matched controls. No anti-dsDNA IgG was detected
in the supernatants from 198 wells from the control fusions;
strong titers, however, were detected in 20/302 wells from
the CD22-deficient mice (18 of these from mouse 9612;
2 from mouse 9449; Fig. 3). Similarly, whereas no cardio-
lipin-specific hybrids were detected in the control fusions,
19 positives were obtained from the CD22-deficient mice
(10 from mouse 9612; 9 from mouse 9449). The majority of
these cardiolipin-specific antibodies were IgMs, although
mouse 9612 gave two IgA and mouse 9449 gave two IgG3
anticardiolipin antibodies.
The hybridomas were then expanded for further charac-
terization. Analysis of the anti-DNA antibodies by surface
plasmon resonance using a biotinylated oligonucleotide as
antigen revealed that several bound DNA very tightly, with
dissociation half-lives in the range of 8–500 min (Fig. 4).
 
 
 
To
ascertain whether the B cells producing these antibodies
were clonally related and whether they had undergone so-
matic hypermutation, the V
 
H
 
 sequences were determined
from several of the anti-DNA antibodies from mouse 9612.
The results demonstrate that the anti-DNA antibodies
within a single CD22-deficient mouse derive from multiple,
clonally expanded B cell progenitors that have undergone
class switching and somatic hypermutation. Thus, for ex-
ample, hybridoma S48 appears to be derived from S30, as
they carry the same V
 
H
 
36–60/J
 
H
 
2 rearrangement but with
S48 harboring multiple additional somatic mutations (sev-
eral to arginine), which could account for its increased af-
finity (Fig. 5 A). Similarly, S31 (IgG1) and S35, S66, S11,
and S15 (all IgG2a) all express the same (V
 
H
 
J558 family
member)/J
 
H
 
2 rearrangement with an arginine-rich CDR3
(characteristic of many anti-DNA antibodies [23–25]); the
individual antibodies differ, however, in the extent of ac-
cumulated somatic mutations (Fig. 5 B). In contrast, S20
and S22 carry distinct rearrangements of the same V
 
H
 
7183
family member (Fig. 5 C). Thus, paralleling observations
previously made with other autoimmune mice (25), multi-
ple independent B cells appear to have seeded an ongoing
anti-DNA response. Similarly, in respect of the two cardio-
lipin-specific IgG3s, analysis of their V
 
H
 
 sequences revealed
them to be clonally related (Fig. 5 D).
 
Discussion
 
The development of autoantibodies in CD22-deficient
mice reveals that a single gene defect exclusive to B cells is
sufficient to trigger autoimmunity in a large proportion of
mice. This presumably means that the restriction of the
provision of T cell help to foreign antigens is intrinsically
imperfect: T cell help for an autoantibody response can be
elicited by a hyperreactive B cell compartment.
The CD22-deficient animals do not, however, go on to
develop autoimmune disease. This is consistent with genetic
analyses of predisposition to systemic autoimmune disease in
lupus-prone mouse strains, which reveal a role for multiple
genetic loci (1–4, 26). Indeed, one of the loci contributing
to autoimmunity in NZM mice (
 
Sle3
 
) has been mapped to
a region of chromosome 7 in the vicinity of 
 
Cd22
 
 and,
when bred into C57BL/6 mice, causes production of IgG
anti-dsDNA antibodies as well as lupus nephritis (27). It will
be interesting to ascertain whether this, at least in part, re-
flects a functionally relevant 
 
Cd22
 
 polymorphism.
 
 
 
By anal-
ogy with studies in the MRL mouse (28), it will also be in-
teresting to ascertain whether mutations in Fas or its ligand
exacerbate autoimmunity in CD22-deficient mice.
The precise mechanism by which CD22 deficiency pre-
disposes to autoimmunity remains to be definitively identi-
fied, but we believe the hyperresponsiveness of CD22-defi-
cient B cells to BCR ligation is likely to be of central
importance. Phosphorylation of CD22 on its cytoplasmic
tyrosines following BCR ligation is mediated by the Lyn
kinase and leads to the recruitment of the phosphatase SHP1
(29–34). It is therefore notable that deficiencies in either Lyn
or SHP1 both lead to autoimmunity (35–38). However,
this autoimmunity is more severe than that in CD22-defi-
cient animals and is most unlikely to simply reflect defects
in CD22-mediated regulation of BCR. Indeed, the increased
severity probably correlates with both Lyn and SHP-1 be-
ing implicated in signal transduction through multiple cell-
surface receptors, with their functions not being limited to
the B cell lineage.
Thus, the significance of the autoantibody development
in CD22-deficient mice lies in the fact that these autoanti-
bodies arise as a consequence of a relatively mild perturba-
tion that is exclusive to B lymphocytes and that affects the
BCR signaling threshold. Experiments performed using
transgenic mice that have been engineered to express high
affinity autoreactive specificities on a substantial proportion
of their B cells have revealed that the fate of such B cells is
sensitive to modifications in CD22, Lyn, and SHP-1 as
well as other genes that affect BCR signaling (9, 10). Our
findings are entirely consistent with these earlier studies but
reveal that CD22 deficiency alone, without additional con-
Figure 4. Binding kinetics of
the monoclonal anti-DNA anti-
bodies as measured by surface
plasmon resonance. Antibody
binding to a biotinylated ds oli-
godeoxyribonucleotide immobi-
lized on streptavidin bound to
the chip is depicted in resonance
units and was monitored as a
function of time. The dissocia-
tion half-life (min) calculated for
each antibody is indicated in pa-
rentheses. The S19 (anticardio-
lipin) antibody (center) was in-
cluded as a negative control. 
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trivance, is sufficient to predispose autoimmunity in normal
animals.
It is attractive to speculate from our results that the major
physiological function served by CD22 in normal mice is
to mediate the avoidance of autoimmunity. In light of the
diminished level of CD22 expression in immature B cells
(39), we previously suggested (11) that CD22 plays a role
in raising the threshold of sensitivity to antigen that accom-
panies differentiation of an immature B cell (sensitive to
tolerization/deletion by low affinity antigen) into a mature
B cell that awaits triggering by exogenous antigen (40). Such
a proposal could well explain the autoimmunity in CD22-
deficient mice. However, a role for CD22 should also take
into account the specificity of its extracellular domain for
 
a
 
-2,6-sialoglycoconjugates (18). Intriguingly, the sialylated
moieties present on eukaryotic membranes enhance the in-
teraction between complement components C3b and fac-
tor H, thereby leading to inhibition of the alternative com-
plement pathway; this serves to bias activation of the innate
immune system toward microbial infection and away from
autoreactivity (41, 42). Maybe CD22 recognition of the
sialoglycoconjugates expressed on mammalian cells serves
an analogous role in the adaptive immune system, dampen-
ing the BCR signaling that might otherwise be triggered
by low affinity autoantigens. It will be interesting to ascer-
tain whether making mutations in the CD22 extracellular
domain that abolish recognition of sialoglycoconjugates
will be sufficient to predispose autoimmunity.
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Figure 5. VH sequences of autoantibodies. Amino acid numbering is according to Kabat. The identity of the underlined amino acids is determined by
the forward-priming oligonucleotide. (A–C) Sequences of anti-DNA antibodies, derived from a single fusion performed on an 18-mo-old female CD22-
deficient mouse (9612) from the BALB/c breedings. (A) Sequences of the clonally related anti-DNA antibodies S30 and S48, which use a VH36–60/JH2
rearrangement. The parental germline VH could not be unambiguously assigned, but, based on VH36–60 sequences in the database, S30 is likely to prove
much closer to the germline sequence than S48. (B) VH amino acid sequences compared with a family of clonally related hybrids (S31, S35, S11, S15, and
S66). G/L indicates the presumed sequence of the parental germline VH (J558 family member) from which these sequences derive, deduced on the basis
of intraclonal sequence comparison as well as the published database of VH sequences. Hybridoma S47 from the same fusion uses a distinct but related VH
rearrangement. (C) Sequences of S20 and S22, which use different rearrangements of VH61–1P (a VH7183 family member [43]) as their germline progen-
itor. (D) Sequences of clonally related anticardiolipin IgG3s (obtained from mouse 9449), which use a VHJ558/JH2 rearrangement. Dashes, identities; pe-
riods, silent nucleotide substitutions.1312 Autoantibodies in CD22-deficient Mice
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